Chronic non-infectious posterior uveitis: Dissecting real-world registry study of YUTIQ
October 12th 2021Dr Ankur Shah discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.
OCULUS joins International Myopia Institute in mission to raise myopia awareness
August 11th 2021OCULUS has combined efforts with International Myopia Institute to raise awareness of myopia and drive scientific advancements to prevent sight-threatening complications and blindness, which may arise as a result.
Application for Genentech’s faricimab accepted by U.S. FDA for treatment of wet AMD and DMO
August 3rd 2021If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.
Gene therapy helps patient with retinitis pigmentosa achieve partial vision
May 26th 2021An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.
Johnson & Johnson Vision, Alcon engaged in intellectual property dispute
May 18th 2021After a US District judge rules against request for preliminary injunction, Johnson & Johnson Vision moves forward with litigation in several countries, including the United States, to resolve intellectual property disputes against Alcon.
Measuring visual fields with cloud-based AI platform
May 7th 2021Dr Mohamed Abou Shousha and Dr Richard Parrish II discuss their ARVO 2021 presentation regarding a study analyzing visual field measurements using the Heru Visual Field Multi-platform application downloaded on two different commercially available augmented reality devices.
Looking at 10 years of dry eye disease flares
May 6th 2021Dr Christopher Starr discusses key points from his virtual ARVO 2021 presentation regarding dry eye disease flares, including a rapid readout assessment of 10 years' worth of world literature to analyze studies in which the inflammatory disease's condition are categorized.
Clinical results analyze dexamethasone implant effect on macular thickness
May 5th 2021Dr. Daniel F. Kiernan discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.
Targeting neurodegenerative diseases using risuteganib
May 3rd 2021Dr Glenn J. Jaffe discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.